Protalix BioTherapeutics (DE) (PLX) vs SAB Biotherapeutics (SABS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Protalix BioTherapeutics (DE) (PLX) has outperformed SAB Biotherapeutics (SABS) over the past year, gaining 65.7% versus a loss of 28.9%. Over five years, PLX leads with a +192.9% price change compared with -97.3% for SABS. SAB Biotherapeutics is the larger company by market cap ($253.1 million vs $244.5 million), about 1.0 times the size, while Protalix BioTherapeutics (DE) is growing revenue faster (-1.2% vs -100.0%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PLX | SABS |
|---|---|---|
| Share price | $2.90 | $2.81 |
| Market cap | $244.52M | $253.15M |
| 1-day change | -5.23% | -3.44% |
| YTD return | +61.11% | -24.87% |
| 1-year return | +65.71% | -28.86% |
| 5-year return | +192.93% | -97.32% |
| P/E ratio (TTM) | 12.08 | — |
| Forward P/E | 4.68 | — |
| EPS (TTM) | $0.24 | $-1.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $52.74M | $0 |
| Revenue growth (YoY) | -1.23% | -100.00% |
| Net income (latest FY) | $-6.60M | $13.27M |
| Gross margin | 48.82% | — |
| Operating margin | -10.43% | — |
| Net margin | -12.52% | — |
| 52-week high | $3.19 | $5.15 |
| 52-week low | $1.65 | $2.44 |
| Distance from 52-week high | -9.09% | -45.44% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +313.79% | +314.23% |
| Average volume | 903.48K | 633.60K |
| Shares outstanding | 84.32M | 90.09M |
| Employees | 226 | 86 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PLX has outperformed SABS by 94.6 percentage points over the past year.
- Protalix BioTherapeutics (DE) grew revenue faster in its latest fiscal year (-1.23% vs -100.00%).
About Protalix BioTherapeutics (DE)
PLX stock →Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 226 employees
About SAB Biotherapeutics
SABS stock →SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 86 employees
PLX vs SABS FAQ
Which is bigger, Protalix BioTherapeutics (DE) or SAB Biotherapeutics?
SAB Biotherapeutics (SABS) is larger, with a market capitalization of $253.15M compared with $244.52M for Protalix BioTherapeutics (DE) (PLX).
Which stock has performed better over the past year, PLX or SABS?
PLX returned +65.71% over the past 12 months, compared with -28.86% for SABS (price return, excluding dividends). Past performance does not predict future results.
Are Protalix BioTherapeutics (DE) and SAB Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.